Research: Prostrate cancer patients opt for more expensive treatment
Men diagnosed with prostate cancer have been rapidly adopting new, more expensive treatment options, even without proof of their cost-effectiveness, according to research by the Dana-Farber/Brigham and Women’s Hospital Cancer Center.
In a report released this week, the researchers noted that 180,000 men are diagnosed with prostate cancer each year, making it one of the most common types of cancer in the U.S. The ease with which the more expensive options were adopted without proof of cost effectiveness may be indicative of why health care accounts for 17 percent of the U.S. gross domestic product. The research will appear in an upcoming edition of the Journal of Clinical Oncology.